Nav: Home

Liquid biopsies in SOLAR-1 trial predict benefit of Alpelisib in PIK3CA-mutant breast cancer

December 06, 2018

Liquid biopsy-based assessment of PIK3CA mutational status served as a better indicator of progression-free survival compared with analysis of tissue biopsy in breast cancer patients enrolled in the phase III clinical trial SOLAR-1, according to data presented at the 2018 San Antonio Breast Cancer Symposium, held Dec. 4-8.

"While the primary endpoint of the SOLAR-1 trial was determined based on PIK3CA mutations in any available tumor tissue, such as archival or fresh tissue, liquid biopsy analysis can be performed on a plasma sample obtained just prior to the initiation of treatment," said Dejan Juric, MD, director of the Termeer Center for Targeted Therapies at the Massachusetts General Hospital Cancer Center. "Our analysis reveals that advanced breast cancer patients with detectable PIK3CA mutations in their blood have a more impressive benefit when alpelisib [a selective PI3K-alpha inhibitor] is added to fulvestrant for their treatment compared to patients with PIK3CA mutations detected in their tissue."

Utilizing information from the SOLAR-1 trial, Juric and colleagues analyzed data from 341 hormone positive, HER2-negative advanced breast cancer patients with PIK3CA mutations, as determined by tissue biopsy, who had received prior endocrine therapy. Patients were randomized to receive either fulvestrant and alpelisib or fulvestrant and placebo. The median follow-up time was 20 months.

In addition to tissue-based analysis, the researchers evaluated progression-free survival (PFS) by PIK3CA mutational status as measured in circulating tumor DNA (ctDNA). PFS was also analyzed by line of metastatic treatment, and by prior exposure to cyclin-dependent kinase 4/6 (CDK4/6) inhibitors.

While patients with PIK3CA mutations as evaluated in tissue samples had a 35 percent reduction in risk for disease progression, the risk reduction was 45 percent for patients with PIK3CA mutations as evaluated in ctDNA.

"Compared to tissue DNA, circulating tumor DNA is a very easily accessible source of material for mutation profiling," said Juric. "The finding that assessing mutational status via liquid biopsy resulted in even larger clinical benefit compared to tissue biopsy, with improvement of median PFS from 3.7 months to 10.9 months, further highlights the clinical utility of this biospecimen."

Compared with patients in the placebo arm, those who received alpelisib as second line of treatment in the metastatic setting had a 39 percent reduction in risk for disease progression; the risk reduction was 33 percent for those who did not receive prior treatment with CDK4/6 inhibitors. There was also a 52 percent (nonsignificant) reduction in risk for participants who received prior treatment with CDK4/6 inhibitors.

Patients enrolled in the alpelisib arm experienced increased incidences of hyperglycemia, diarrhea, nausea, and rash compared to the placebo arm (65 percent versus 9 percent; 54 percent versus 11 percent; 46 versus 20 percent; and 40 percent versus six percent, respectively).

"PI3K-alpha is important for insulin signaling and PI3K-alpha inhibition results in insulin resistance; hyperglycemia is therefore an on-target effect inextricably linked with the activity of alpelisib," said Juric. "Early detection and serial monitoring of elevated glucose, initiation of appropriate dietary measures, as well as early initiation of metformin and other insulin sensitizers is essential for adequate management of these patients."

Limitations of this study include a small number of patients who received prior treatment with CDK4/6 inhibitors. "Larger studies specifically focused on post-CDK4/6 patients are needed to further characterize the role of alpelisib in this setting," Juric noted.
-end-
The study was sponsored by Novartis. Juric has received scientific advisory board fees from Novartis, Genentech, EMD Serono, Ipsen, and Eisai.

American Association for Cancer Research

Related Disease Progression Articles:

Apathy as an indicator of progression in Huntington's disease
IDIBELL-UB researchers associate changes in white matter connectivity in different subtypes of apathy, one of the most common psychiatric syndromes in Huntington's disease (HD).
Risk and progression of Alzheimer's disease differ by sex
The abnormal accumulation of proteins in the brain is a biological marker for Alzheimer's disease, but the ways in which these proteins spread may help explain why the prevalence of Alzheimer's is higher in women than in men.
Common virus linked to faster disease progression in cystic fibrosis
A new study has found that cystic fibrosis patients who have a common virus may experience faster disease progression than patients who do not have the virus.
New PET imaging biomarker could better predict progression of Alzheimer's disease
Researchers have discovered a way to better predict progression of Alzheimer's disease.
Multiple sclerosis treatments delay progression of the disease
An international study finds multiple sclerosis treatments have long-term benefits, and that early treatment is important.
More Disease Progression News and Disease Progression Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...